Pharmalot

By Ed Silverman

Taking stock of the drug industry, from the lab to the medicine chest. Sign up for the newsletter here.

Drug price jump

Pharmalot

A troubled drug maker attempts to compensate for its problems by taking huge price hikes

By Ed Silverman

Oxycodone bottles

Pharmalot

After three years of controversy, CDC clarifies its opioid prescribing guidelines

By Ed Silverman

advertisement

Pharmalot

Pharmalittle: House Republicans warn pharma over Democrats’ pricing probe; Glaxo wins FDA nod for HIV pill

By Ed Silverman

advertisement

Opioid Crisis Lawsuits

Pharmalot

Cardinal Health is fined by Ohio for failing to secure shipments of controlled substances

By Ed Silverman

Pharmaceutical company Takeda

Pharmalot

European Union files complaint against Turkey for ‘discriminating’ against foreign drug makers

By Ed Silverman

Pharmalot

Pharmalittle: A PBM hearing nears in Congress; the WHO readies a forum on fair drug pricing

By Ed Silverman

Money and medicine

Pharmalot

Advocates say a Commerce Dept. report would preclude reclaiming patents as a way to lower drug prices

By Ed Silverman

advertisement

Hires

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

advertisement

Pharmalot

Pharmalittle: Oklahoma trims claims against J&J and Teva in opioid suit; House committee poised to vote on drug pricing bills

By Ed Silverman

Pharmalot

Amgen and Novartis file dueling lawsuits over their deal to market a migraine drug

By Ed Silverman

Pill Dollars

Pharmalot

A growing number of states are eyeing laws to prohibit a controversial cost-sharing tool

By Ed Silverman

Medical costs photo illustration

Pharmalot

Three drug makers settle allegations of using charities to pay kickbacks to Medicare patients

By Ed Silverman

Pharmalot

Pharmalittle: Oklahoma lawmakers criticize Purdue deal; AbbVie faces more pressure to split top jobs

By Ed Silverman

Patrick Soon-Shiong

Pharmalot

A small drug maker accuses Soon-Shiong of masterminding a ‘catch-and-kill’ scheme

By Ed Silverman

Pharmalot

Pharmalittle: Roche struggles to close Spark deal; Congress zeroes in on insulin makers

By Ed Silverman

Brain

Pharma

A safety watchdog argues the FDA should reconsider approval of a Parkinson’s psychosis drug

By Ed Silverman

Insulin injection

Pharmalot

How much? Medicare Part D spending on insulin has been skyrocketing

By Ed Silverman

Pharmalot

Pharmalittle: AIDS activists heckle CDC director; DEA calls Mallinckrodt an opioid ‘kingpin’

By Ed Silverman

Novartis International pharmaceutical

Pharmalot

After years of delay, Novartis faces an upcoming trial for allegedly paying kickbacks to doctors

By Ed Silverman

Alex Brandon/AP

Pharmalot

FTC rules that a pay-to-delay deal was meant to thwart competition

By Ed Silverman

Pharmalot

Pharmalittle: Novartis strikes an immunotherapy deal; China to regulate all fentanyl-related drugs

By Ed Silverman

Purdue Pharmaceuticals

Pharmalot

Purdue Pharma’s newly created subsidiaries raise questions over attempts to shield assets from bankruptcy

By Ed Silverman

Hires

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Vertex destroyed drugs amid standoff in the U.K.; Sacklers accused of diverting Purdue assets

By Ed Silverman

FDA; Drug Administration campus

Pharmalot

Drug makers continue to clamor for FDA approval of orphan drugs

By Ed Silverman

Pharmalot

Why J&J raced to put drug prices in some TV ads

By Ed Silverman

Pharmalot

Pharmalittle: U.K. adviser complains pharma ignores antibiotics; FDA to revamp manufacturing rules

By Ed Silverman

Jeffrey Leiden

Pharmalot

Are Vertex and the U.K. government inching toward a resolution over a pricey drug?

By Ed Silverman

Pharmalot

Pharmalittle: Gilead and CDC tussle over Truvada patents; Novartis wins FDA approval for an MS drug

By Ed Silverman

« Previous Page